Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Impedance Plethysmography Based Deep Vein Thrombosis Monitoring During Catheter-directed Thrombolysis

24 juni 2026 uppdaterad av: Antti Vehkaoja, Tampere University

The purpose of this study is to collect data on blood circulation using a multi-frequency impedance plethysmography device developed in the ThrombUS+ project. Impedance plethysmography (IPG) is a non-invasive method that measures changes in blood volume using electrodes placed on the skin. The collected data will be used for device development, the improvement of diagnostic data analysis methods, and AI training.

A total of 40 participants will be recruited for this study, with 20 healthy volunteers in Tampere University and 20 patients undergoing thrombolytic therapy for DVT at Tampere University Hospital.

Studieöversikt

Status

Rekrytering

Betingelser

Intervention / Behandling

Detaljerad beskrivning

This study aims to collect IPG data set from healthy volunteers and DVT patients using ThrombUS+ prototype device developed during the project and commercial IPG device as a reference. The data will be used to develop ThrombUS+ IPG device, its signal processing and analysis algorithms and to train ML models.

Objectives of the study are to

  1. Collect IPG data for developing signal processing, data analysis and ML algorithms for DVT detection and assessment.
  2. Evaluate the performance of the developed methods to gold standard references including angiography, ultrasound imaging and venous occlusion plethysmography.
  3. Investigate whether multi-frequency IPG measurement improves the performance of DVT detection compared to single frequency measurement and determine the optimal measurement frequency.
  4. Investigate and compare different interventions to cause changes in venous blood volume for DVT detection, such as venous occlusion by thigh cuff, active respiration and muscle activation.

Secondary objectives are

1) To investigate methods for simulating DVT and to compare the performance of these methods for DVT simulation.

Studietyp

Observationell

Inskrivning (Beräknad)

40

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

  • Finland
      • Tampere, Finland
        • Rekrytering
        • Tampere University Hospital
        • Kontakt:
      • Tampere, Finland
        • Avslutad
        • Tampere University

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Ja

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Tampere

Beskrivning

Inclusion Criteria for Patients group:

  • Age: 18 or older;
  • DVT detected on other lower limb;
  • Suitable for CDT treatment;
  • Ability to give informed consent;
  • Volunteering for the study.

Exclusion Criteria for Patients group:

  • Age under 18 years;
  • Inability to give informed consent;
  • Denial;
  • Too injured skin in the measurement area

Inclusion Criteria for Healthy volunteers group:

  • Age: 18 or older;
  • Ability to give informed consent;
  • Volunteering for the study

Exclusion Criteria for Healthy volunteers group:

  • Diagnosed DVT in lower limbs;
  • Age under 18 years;
  • Inability to give informed consent;
  • Denial;
  • Too injured skin in the measurement area.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Friska volontärer
Enhet: Impedance plethysmography IPG
IPG signal is measured with ThrombUS+ prototype device
Andra namn:
  • IPG
Enhet: Venous Occlusion Plethysmography VOP
In VOP measurement, a temporal blood restriction is caused by an occlusive cuff blocking venous outflow but allowing arterial inflow. The cuff intervention causes a change in venous blood volume, and it can be measured by electrical impedance plethysmography (IPG).
Andra namn:
  • VOP
Övrig: Breathing and leg movement exercise
The first exercise is the Valsalva maneuver, where the subject first inhales and then pushes out the breath while the larynx is closed. In the second exercise, the subject inhales for approximately 10 seconds, holds the breath for approximately 5 seconds, and then breathes out. Finally, the subject moves the ankles to contract calf muscles, and further to cause changes in venous blood volume. The IPG signal is measured on both calves by ThrombUS+ prototype device during these exercises.
Andra namn:
  • Valsalva
Patients
DVT detected on other lower limb, undergoing catheter-directed thrombolysis
Enhet: Impedance plethysmography IPG
IPG signal is measured with ThrombUS+ prototype device
Andra namn:
  • IPG
Enhet: Venous Occlusion Plethysmography VOP
In VOP measurement, a temporal blood restriction is caused by an occlusive cuff blocking venous outflow but allowing arterial inflow. The cuff intervention causes a change in venous blood volume, and it can be measured by electrical impedance plethysmography (IPG).
Andra namn:
  • VOP
Övrig: Breathing and leg movement exercise
The first exercise is the Valsalva maneuver, where the subject first inhales and then pushes out the breath while the larynx is closed. In the second exercise, the subject inhales for approximately 10 seconds, holds the breath for approximately 5 seconds, and then breathes out. Finally, the subject moves the ankles to contract calf muscles, and further to cause changes in venous blood volume. The IPG signal is measured on both calves by ThrombUS+ prototype device during these exercises.
Andra namn:
  • Valsalva

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Impedance plethysmography (IPG) data during CDT treatment
Tidsram: From enrollment to the end of the CDT treatment (up to 2 days)
From enrollment to the end of the CDT treatment (up to 2 days)
Impedance plethysmography (IPG) data from healthy volunteers
Tidsram: From enrollment to the end of measurements (up to 2 hours)
From enrollment to the end of measurements (up to 2 hours)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Tampere University

Samarbetspartners

Tampere University Hospital

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

17 juli 2025

Primärt slutförande (Beräknad)

1 december 2027

Avslutad studie (Beräknad)

1 december 2027

Studieregistreringsdatum

Först inskickad

15 maj 2026

Först inskickad som uppfyllde QC-kriterierna

23 juni 2026

Första postat (Faktisk)

24 juni 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

29 juni 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

24 juni 2026

Senast verifierad

1 juni 2026

Mer information

Termer relaterade till denna studie

Nyckelord

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • ThrombUS+B4

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera